Krabbe Disease

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
The endocannabinoid system as a target for the treatment of neurodegenerative disease
The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

CONTACT

845-988-HEMP

contact@fusioncbd.com

Want to learn more and try Fusion CBD for free?

Let’s grow together #fusionfam

© 2017 - 2020 Fusion Holding Group. All Rights Reserved.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. The Federal Food, Drug and Cosmetic Act requires this notice.